Fig. 2

Treatment of PR-AKI cats by using the infusion with ADMSCEVs. A ADMSCs morphology and its differentiation into adipose and cartilage defined by oil red staining and alizarin red staining, respectively. B Transmission electron microscopy images of ADMSCEVs. Left panel, typical vesicle structure of ADMSCEVs, right panel, the enlarged ADMSCEVs. C Western blotting of ADMSCEVs marker protein TSG101 and CD63. The number 1, 2, 3 indicate three independent samples of ADMSCEVs. MW, molecular weight. D Particle sizes distribution of ADMSCEVs. E Schematic diagram of different treatment procedures for PR-AKI cats. CGS: Ceftiofuroxime sodium (C); Glucose (G); Sodium chloride (S). F Dynamic fold changes in creatinine level of PR-AKI cats treated by control infusion and ADMSCEVs. CRE FC, creatinine fold changes. G Average folds changes of creatinine level per hour in the first 24 h of treatment with the control infusion and ADMSCEVs. Statistical analyses were performed using two-tailed unpaired t test, *P < 0.05. H Dynamic fold changes in blood urea nitrogen level of PR-AKI cats treated by control infusion and ADMSCEVs. BUN FC, blood urea nitrogen fold changes. I Average folds changes of blood urea nitrogen (BUN) level per hour in the first 24 h of treatment with the control infusion and ADMSCEVs. Statistical analyses were performed using two-tailed unpaired t test, *P < 0.05. J Fold changes in body temperature of PR-AKI cats treated with control infusion and ADMSCEVs. NS not significant